U.S. Markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.59-1.35 (-10.43%)
At close: 4:00PM EDT
11.59 0.00 (0.00%)
After hours: 04:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.94
Open12.69
Bid11.25 x 1800
Ask11.54 x 3100
Day's Range11.35 - 12.77
52 Week Range9.01 - 21.30
Volume1,384,022
Avg. Volume534,239
Market Cap543.493M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-3.83
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.27
  • Business Wire

    Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition

    DURHAM, N.C., September 20, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment Erik Pacyniak, Ph.D., D.A.B.T., Director, Toxicology, reporting to Jeff White, Ph.D., D.A.B.T., Aerie’s Vice President of Research and Discovery. Dr. Pacyniak will o

  • Zacks

    Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

    AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

  • Benzinga

    56 Biggest Movers From Yesterday

    Check out these big penny stock gainers and losers Losers Vera Therapeutics, Inc. (NASDAQ: VERA) shares tumbled 26.5% to settle at $22.48. MacroGenics, Inc. (NASDAQ: MGNX) fell 23.8% to close at $20.99 as the company disclosed results from Cohort A Part 1 of the Phase 2/3 MAHOGANY clinical trial of margetuximab. Silverback Therapeutics, Inc. (NASDAQ: SBTX) shares dipped 23.1% to close at $12.50 on Thursday. The company presented interim clinical results from a Phase 1/1b clinical study of SBT605